Interpace Biosciences (IDXG) Tops Q2 EPS by 17c

Interpace Biosciences (OTC: IDXG) reported Q2 EPS of $0.09, $0.17 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $11.03 million versus the consensus estimate of $13 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Accenture downgraded by TD Cowen on AI concerns